The recently approved antiviral drug letermovir lowered the risk for clinically significant cytomegalovirus (CMV) infection compared with placebo in CMV-seropositive recipients of allogeneic hematopoietic cell transplant (allo-HCT) in a recent study.
In the phase 3, placebo-controlled study (N Engl J Med 2017;377[12]:2433-2444), investigators administered letermovir (Prevymis, Merck) (480 mg daily or 240 mg daily in patients taking cyclosporine) (n=325), or placebo (n=170) to CMV-positive